MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why LEXX Stock surged +14.24% Today — RQD Quant Desk Flash
$3.77 +14.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.86
Lexaria Bioscience Corp. (LEXX) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $7.9M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.86 (+2.37%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LEXX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY LEXX SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (28% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (23% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.32-13.9% Next Q
39
Q2 (-2Q)Grade D$2.86+7.7% Next Q
42
Q3 (-1Q)Grade D$3.08+22.4% Next Q
44
CurrentGrade D$3.77-5.9% Hist 90D α
47
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a LEXX Turnaround Squeeze
While LEXX currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.27) and Max Pain ($3.96) forces dealer call-delta covering toward $22.68.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LEXX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LEXX Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LEXX Stock surged +14.24% Today — RQD Quant Desk Flash
Lexaria Bioscience Corp. (LEXX) surged +14.24% to $3.77, trading at 7% of its 52-week range ($2.43 – $21.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 7% of its 52-week range ($2.43 – $21.6) with RSI-14 at 48.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.77 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 70.3% gross margin and $0 annual free cash flow.
Live LEXX Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LEXX)
- ✓Walkthrough of LEXX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LEXX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -61.88%📐 HORIZONTAL RANGE
2026-10-30O $3.63H $3.77L $3.09C $3.77VOL 37.7K
RES: $15.94SUP: $1.34SMA50: $5.27SMA200: $8.96
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LEXX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +52.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on LEXX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LEXX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LEXX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LEXX)
Health Care Rank #427 of 1016
⚔️ SNGX vs LEXX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LEXX vs. SNGX, MTVA, TCRT, KPRX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Lexaria Bioscience Corp. (LEXX) ranks #427 by composite RQD confidence (47/100, grade D) and #912 by equity capitalization ($7.9M). Within this direct 5-issuer industry benchmark cohort, LEXX leads on earnings valuation at N/A trailing P/E, while LEXX leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. LEXX currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LEXX
ACTIVE
Lexaria Bioscience Corp. | D | 47/100 | — | 96.0% | -35.0% | +14.24% | $7.9M | Benchmark Subject |
| SNGX Soligenix Inc. | D | 44/100 | — | — | -35.0% | -1.55% | $8.0M | /sngx-vs-lexx → |
| MTVA MetaVia Inc. | D | 47/100 | — | — | -35.0% | +4.39% | $7.8M | /mtva-vs-lexx → |
| TCRT Alaunos Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -11.27% | $7.8M | /tcrt-vs-lexx → |
| KPRX Kiora Pharmaceuticals Inc. | E | 32/100 | — | — | -35.0% | -25.42% | $7.8M | /kprx-vs-lexx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-08-31 • CIK 0001348362In its most recent audited fiscal period (FY2025, filed 2025-08-31), Lexaria Bioscience Corp. (LEXX) reported GAAP revenue of $705.9K (+52.0% vs. FY2024 revenue of $464.3K , and +212.1% cumulative change since FY2023) , GAAP net income of -$11.9M, operating cash flow of -$10.5M, and free cash flow of -$10.5M (-109.4% YoY). On the balance sheet, LEXX closed FY2025 with $6.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-08-31 | $705.9K | -$11.9M | -$10.5M | -$10.5M | $6.1M | — |
| FY2024 (FY) | 2024-08-31 | $464.3K | -$5.8M | -$5.0M | -$5.0M | $9.8M | — |
| FY2023 (FY) | 2023-08-31 | $226.2K | -$6.7M | -$5.9M | -$5.9M | — | — |
3. LEXX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LEXX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Lexaria Bioscience Corp. (NASDAQ: LEXX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $3.77 (+14.24% 1D, market cap $7.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LEXX ranks #427 in composite RQD confidence.
How does LEXX compare to SNGX and MTVA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LEXX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, SNGX (Soligenix Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $8.0M) and MTVA (MetaVia Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M). Among the 5-stock peer group, LEXX leads on earnings multiple (N/A) while LEXX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LEXX?
Per LEXX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-08-31, CIK 0001348362), Lexaria Bioscience Corp. generated $705.9K in revenue (+52.0% YoY), -$11.9M in net income, and -$10.5M in free cash flow against $6.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LEXX trading relative to its 50-day, 200-day, and 52-week technical levels?
LEXX last traded at $3.77 (+14.24% on volume of 39,310 shares), positioning the stock -28.46% below its 50-day simple moving average ($5.27) and -57.92% below its 200-day simple moving average ($8.96). Across its 52-week range of $2.43 to $21.60, LEXX sits at the 7.0% percentile with a 14-day RSI of 48.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.30 to $4.24).
LEXX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is LEXX stock moving today?
Why LEXX Stock surged +14.24% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.